Gastroenterology
Volume 134, Issue 7 , Pages 1972-1980, June 2008

A Green Tea Component Suppresses Posttranslational Expression of Basic Fibroblast Growth Factor in Colorectal Cancer

  • Mugdha Sukhthankar

      Affiliations

    • Laboratory of Environmental Carcinogenesis, Department of Pathobiology, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee
  • ,
  • Kiyoshi Yamaguchi

      Affiliations

    • Laboratory of Environmental Carcinogenesis, Department of Pathobiology, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee
  • ,
  • Seong–Ho Lee

      Affiliations

    • Laboratory of Environmental Carcinogenesis, Department of Pathobiology, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee
  • ,
  • Michael F. McEntee

      Affiliations

    • Laboratory of Environmental Carcinogenesis, Department of Pathobiology, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee
  • ,
  • Thomas E. Eling

      Affiliations

    • Laboratory of Molecular Carcinogenesis, NIEHS, Research Triangle Park, North Carolina
  • ,
  • Yukihiko Hara

      Affiliations

    • Mitsui Norin Co., Ltd, Food Research Lab, Miyabara, Fujieda City, Japan
  • ,
  • Seung Joon Baek

      Affiliations

    • Laboratory of Environmental Carcinogenesis, Department of Pathobiology, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee
    • Corresponding Author InformationAddress requests for reprints to: Seung Joon Baek, PhD, Department of Pathobiology, College of Veterinary Medicine, University of Tennessee, 2407 River Dr, Knoxville, Tennessee 37996. fax: (865) 974-5616.

Received 28 September 2007; accepted 28 February 2008. published online 10 March 2008.

Background & Aims: Green tea catechins are known to have anticarcinogenic effects. Epigallocatechin-3-gallate (EGCG) accounts for almost 50% of the total catechin content in green tea extract and has very potent antioxidant effects. EGCG also inhibits angiogenesis, possibly through the inhibition of proangiogenic factors including vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), which in turn, inhibits tumor growth and metastasis. However, the exact molecular mechanism by which EGCG suppresses bFGF expression is not known. Our objective was to elucidate the molecular mechanisms by which EGCG inhibits bFGF expression in colorectal cancer. Methods: We examined posttranslational regulation of bFGF by EGCG in human colorectal cancer cells. We also examined bFGF in intestinal tumor formation of APCMin/+ mice with and without catechin treatment. Results: The bFGF protein was quickly degraded in the presence of EGCG, but a proteasome inhibitor suppressed this degradation. EGCG was also found to increase ubiquitination of bFGF and trypsin-like activity of the 20S proteasome, thereby resulting in the degradation of bFGF protein. Furthermore, EGCG suppressed tumor formation in APCMin/+ mice, compared with vehicle-treated mice, in association with reduced bFGF expression. Conclusions: The ubiquitin-proteasome degradation pathway contributes significantly to down-regulation of bFGF expression by EGCG. Catechin compounds have fewer adverse effects than chemotherapeutic agents and hence can be used as proof-of-concept in cancer therapeutics to suppress growth and metastasis by targeting proteins such as bFGF.

Abbreviations used in this paper: bFGF, basic fibroblast growth factor, ECG, epicatechin-3-gallate, EGCG, epigallocatechin 3-gallate, VEGF, vascular endothelial growth factor

 

 Supported primarily by NIH grant R21CA109423 (to S.J.B.) and K26RR016645 (to M.F.M.).Conflicts of interest: No conflicts of interest exist.

PII: S0016-5085(08)00432-0

doi:10.1053/j.gastro.2008.02.095

Gastroenterology
Volume 134, Issue 7 , Pages 1972-1980, June 2008